Skip to main content

Table 4 Important human NK cell receptors in cancer immunotherapy

From: Immunodynamics: a cancer immunotherapy trials network review of immune monitoring in immuno-oncology clinical trials

Receptor family Cluster of Designation Ligand
Activating receptors   
FcγRIIIa (CD16) CD16 Immunoglobulin G
DNAM-1 CD226 Nectin-2 (CD112), PVR (CD155)
NKG2D CD314 MICA, MICB, ULBPs
NKp46 CD335 Viral HA, HN
NKp30 CD337 B7-H6
2B4 CD244 CD48
CS1 CD319 CS1
NKG2C CD158c HLA-E
KIR2DS1/2/3 CD158h,j HLA-C2
NKp80 n/a AICL
Inhibitory receptors   
KIR2DLs CD158a,b HLA-C1,C2
KIR3DLs CD158,e,f,k HLA-A,B
NKG2A CD159a HLA-E
LIR-1 CD85j HLA-A,B,C
   (allele-specific HLA-B and HLA-C)
Adhesion/Trafficking receptors   
N-CAM CD56 CD56, FGFR1
L-selectin CD62L GlyCAM-1, CD34, PSGL-1
PEN-5/PSGL-1 CD162 Selectins
LFA-1 CD11a ICAMs
LFA-2 CD2 CD58
LFA-3 CD58 CD2
αMβ2 CD11b fibrinogen, C3bi, ICAM-4